The Infectious Diseases Society of America rolled out its first-ever guidelines for treating methicillin-resistant Staphylococcus aureus – including recommendations to battle the growing threat posed by MRSA-related skin and soft-tissue infections. The comprehensive guidelines also outline evidence-based approaches on topics ranging from personal hygiene and wound care to antibiotic therapies for invasive MRSA, as well as options after vancomycin treatment failure. The guidelines give advice on uncomplicated and serious MRSA infections, according to Catherine Liu, MD, lead author and assistant clinical professor in the division of infectious diseases, University of California, San Francisco. MRSA infections account for about 60% of skin infections seen in U.S. emergency departments, and invasive MRSA infections cause about 18,000 deaths a year, according to the Infectious Diseases Society of America (IDSA). The evidence-based guidelines, published in the Feb. 1 issue of Clinical Infectious Diseases (Clin. Infect. Dis. 2010 [doi:10.1093/cid/ciq146]), are voluntary and “are not intended to take the place of a doctor's judgment, but rather support the decision-making process, which must be individualized according to each patient's circumstances,” according to a statement issued by IDSA, which funded the guidelines. A 13-member expert panel reviewed hundreds of scientific studies, papers, and presentations to create the recommendations. The guidelines' sections start with a clinical question, followed by a numbered list of recommendations and a summary of the most relevant evidence to support the recommendations. The guidelines also highlight areas of limited or conflicting data. The first topic addressed is the management of skin and soft tissue infections due to MRSA, which have become a significant problem over the last decade, Dr. Liu said in an interview. For example, MRSA is now the predominant organism causing purulent skin infections in patients who present to emergency departments, she noted. The guidelines address several types of skin infections, including abscesses, cellulitis, and more complicated ones. The guidelines also offer recommendations on the role of antibiotics, including situations in which they may not be indicated and circumstances where they are recommended. They also offer guidance “on specific antibiotic choices for the different types of skin infections,” Dr. Liu noted. Other topics covered include the management of MRSA pneumonia, bacteremia, and infective endocarditis; central nervous system infections; and bone and joint infections. Additional sections review the role of adjunctive therapies in the treatment of MRSA infections and specific recommendations on vancomycin dosing and monitoring. IDSA will update the guidelines as more information and newer antibiotics become available. However, timely updating can be difficult because of the review and publication process, Dr. Liu noted. For example, the Food and Drug Administration approved the intravenous cephalosporin antibiotic ceftaroline in October 2010 for acute bacterial skin and soft tissue infections, including cases caused by MRSA. But approval came after the IDSA guidelines were finalized, and that information was not included. The guidelines do not address active surveillance testing or other strategies aimed at preventing MRSA in health care settings, topics that have been addressed in previously released guidelines. IDSA funded the development of the guidelines, now available in full online at http://cid.oxfordjournals.org/content/early/2011/01/04/cid.ciq146.full.pdf+html. Of the expert panel's 13 members, 9 reported receiving honoraria or research support from, various pharmaceutical companies, Dr. Liu and three others, reported no conflict. Elizabeth Mechcatie is a senior writer with Elsevier Global Medical News.
Read full abstract
Mar 1, 2016
Kuang-Wei Chou + 3
Open Access
